Transplacental passage of belimumab during pregnancy and follow-up of a child exposed in utero

Ann Rheum Dis. 2023 Apr;82(4):577-579. doi: 10.1136/ard-2022-223684. Epub 2023 Jan 5.

Authors

Helle Bitter¹, David John Warren², Nils Bolstad², Anne LIndtner Noraas³, Monika Elisabeth Ostensen⁴

Affiliations

¹ Department of Rheumatology, Sorlandet Hospital Kristiansand, Kristiansand, Norway helle.bitter@sshf.no.
² Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
³ Rheumatology Specialists of Kristiansand, Kristiansand, Norway.
⁴ Department of Rheumatology, Sorlandet Hospital Kristiansand, Kristiansand, Norway.

PMID: 36604152
DOI: 10.1136/ard-2022-223684

No abstract available

Keywords: Autoimmune Diseases; B-Lymphocytes; Biological Therapy; Lupus Erythematosus, Systemic; Vaccination.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Female
Follow-Up Studies
Humans
Immunosuppressive Agents
Lupus Erythematosus, Systemic* / drug therapy
Pregnancy
Treatment Outcome

Substances

belimumab
Antibodies, Monoclonal, Humanized
Immunosuppressive Agents